Re: ZEN-3694 mCRPC Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 mCRPC Trial Status

in response to

Re: ZEN-3694 mCRPC Trial Status

BearDownAZ

posted on Oct 26, 2017 01:28PM

Toniv,

Look back at Masila's unofficial transcript from the Jan 2016 Zenith AGM....in particular the Q&A session. He addressed many of your recent concerns there.....however, it will be great to revisit these topics at the 2017 AGM on Dec 12 to hear what DM's current thinking is on this.